Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Next Previous
Trial Profile

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixotatug vedotin (Primary) ; Bevacizumab; Pegfilgrastim
  • Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Testicular cancer
  • Focus Adverse reactions; First in man
  • Acronyms TRIO049
  • Sponsors TORL Biotherapeutics

Most Recent Events

  • 18 Jun 2026 According to a TORL BioTherapeutics media release, data from the trial were presented at the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.
  • 18 Jun 2026 Results presented in the TORL BioTherapeutics Media Release
  • 07 Oct 2025 According to a TORL BioTherapeutics media release, updated results from the ongoing Phase 1 study will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025) in Berlin, Germany.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top